Accessing diverse bicyclic peptide conformations using 1,2,3-TBMB as a linker

06 February 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Bicyclic peptides are a powerful modality for the engagement of challenging drug targets such as protein-protein interactions. The most common crosslinkers used to generate bicyclic peptides are C3-symmetrical, with evenly positioned peptide loops facing radially outwards from a linker core to favour globular conformations. In contrast, linkers with alternative symmetries can potentially provide access to a more diverse conformational landscape of bicyclic peptides. Here, we use 1,2,3-tris(bromomethyl) benzene (1,2,3-TBMB) to access bicyclic peptides with multiple isomeric configurations, leading to conformations that differ substantially from both the parent linear peptides and the conventional bicyclization products formed with 1,3,5-TBMB, as observed in 2D NMR and CD experiments. Bicyclization at cysteine residues proceeds efficiently under standard aqueous buffer conditions, with broad substrate scope, compatibility with high-throughput screening, and clean conversion (>90%) of linear precursors to bicyclic products for 88 of the 106 diverse peptide sequences tested. We envisage that the 1,2,3-TBMB linker will be applicable to a variety of peptide screening techniques, thereby enabling the discovery of unconventional bicyclic peptides that can engage a broad range of novel drug targets.

Keywords

Bicyclic peptides

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
SI methods and characterisation
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.